By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11095 Flintkote Avenue
Suite D
San Diego  California  92121  U.S.A.
Phone: Fax:



Company News
Ignyta (RXDX) To Participate In Precision Medicine Panel Discussions With Other Thought Leaders 9/17/2014 12:30:42 PM
Ignyta (RXDX) Announces RXDX-101 Phase I Data Presentation At The 2014 ESMO Congress 9/16/2014 1:03:35 PM
Ignyta (RXDX) Appoints Robert Wild, Ph.D., As Chief Scientific Officer And Senior Vice President, Research 9/8/2014 10:07:41 AM
Ignyta (RXDX) Announces Second Quarter 2014 Company Highlights And Financial Results 8/13/2014 7:55:49 AM
Ignyta (RXDX) Appoints Adrian Senderowicz, M.D., As Chief Medical Officer And Senior Vice President, Clinical Development And Regulatory Affairs 8/11/2014 8:23:36 AM
Ignyta (RXDX) To Report 2014 Second Quarter Company Highlights And Financial Results And Host Conference Call On August 12, 2014 8/7/2014 10:35:19 AM
Ignyta (RXDX) And Nerviano Medical Sciences (NervianoMS) Announce License Agreement For Two First-in-Class Kinase Inhibitors 8/5/2014 10:28:01 AM
Ignyta (RXDX) Announces Initiation Of STARTRK-1 Global Phase I/II Clinical Trial Of RXDX-101 7/21/2014 11:21:37 AM
Ignyta (RXDX) To Be Added To Russell Microcap® Index 6/25/2014 11:44:30 AM
Ignyta Announces Interim Data From RXDX-101 Phase I Clinical Trial 6/2/2014 9:30:49 AM